日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CXCR6(+) T Cells Drive Immune Checkpoint Inhibitor Myocarditis.

CXCR6(+) T 细胞驱动免疫检查点抑制剂心肌炎。

Munir Amir Z, Gutierrez Alan, Krawiec Cade J, Manandhar Priyanka, Shyani Anya C, Ma Pan, Gougis Paul, Baylis Richard A, Hou Lifei, Remold-O'Donnell Eileen, Balko Justin M, Salem Joe-Elie, Lavine Kory J, Lichtman Andrew H, Qin Juan, Moslehi Javid J

CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer.

肿瘤微环境中的 CD8+ T 细胞调节乳腺癌对内分泌治疗的反应。

Napolitano Fabiana, Wang Yunguan, Sudhan Dhivya R, Gonzalez-Ericsson Paula I, Formisano Luigi, Unni Nisha, Shakeel Shahbano, Zhu James Z, Ahuja Khushi, Guo Lei, Chica-Parrado María Rosario, Matsunaga Yuki, Luna Pamela, Lin Chang-Ching A, Uemoto Yasuaki, Lee Kyung-Min, Ma Hongli, Evans Nathaniel J, Servetto Alberto, Mendiratta Saurabh, Barnes Spencer D, Bianco Roberto, Fang Yisheng V, Xu Lin, Lee Jeon, Wang Tao, Balko Justin M, Mills Gordon B, Labrie Marilyne, Hanker Ariella B, Arteaga Carlos L

[Expression of Concern] MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion

【关注事项】MUC1是STAT3的下游靶点,调控肺癌细胞的存活和侵袭。

Gao, Jingchun; Mcconnell, Matthew J; Yu, Bin; Li, Jiannong; Balko, Justin M; Black, Esther P; Johnson, Joseph O; Lloyd, Mark C; Altiok, Soner; Haura, Eric B

KDM4C inhibition blocks tumor growth in basal breast cancer by promoting cathepsin L-mediated histone H3 cleavage.

KDM4C 抑制剂通过促进组织蛋白酶 L 介导的组蛋白 H3 裂解来阻断基底型乳腺癌的肿瘤生长

Li Zheqi, Peluffo Guillermo, Stevens Laura E, Qiu Xintao, Seehawer Marco, Tawawalla Amatullah, Huang Xiao-Yun, Egri Shawn B, Raval Shaunak, McFadden Maeve, D'Santos Clive S, Papachristou Eva, Kingston Natalie L, Nishida Jun, Evans Kyle E, Seo Ji-Heui, Clement Kendell, Temko Daniel, Ekram Muhammad, Li Rong, Rees Matthew G, Ronan Melissa M, Roth Jennifer A, Simeonov Anton, Kales Stephen C, Rai Ganesha, Lal-Nag Madhu, Maloney David J, Jadhav Ajit, Michor Franziska, Meissner Alex, Balko Justin M, Carroll Jason S, Freedman Matthew L, Jaffe Jacob D, Papanastasiou Malvina, Long Henry W, Polyak Kornelia

Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody-STING agonist conjugates

利用模块化白蛋白-搭便车纳米抗体-STING激动剂偶联物增强癌症免疫疗法

Kimmel, Blaise R; Arora, Karan; Chada, Neil C; Bharti, Vijaya; Kwiatkowski, Alexander J; Finkelstein, Jonah E; Hanna, Ann; Arner, Emily N; Sheehy, Taylor L; Pastora, Lucinda E; Yang, Jinming; Pagendarm, Hayden M; Stone, Payton T; Hargrove-Wiley, Ebony; Taylor, Brandie C; Hubert, Lauren A; Fingleton, Barbara M; Gibson-Corley, Katherine N; May, Jody C; McLean, John A; Rathmell, Jeffrey C; Richmond, Ann; Rathmell, W Kimryn; Balko, Justin M; Wilson, John T

Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial

新辅助紫杉醇联合帕博利珠单抗治疗激素受体阳性乳腺癌的疗效、安全性及预测性生物标志物:一项随机试点试验

Waks, Adrienne G; Fu, Jingxin; Chu, Xiangying; Binboga Kurt, Busem; Li, Tianyu; Kuntz, Thomas M; Shen, Yizhuo; Yang, David; Meli, Kevin; Reardon, Brendan; Park, Jihye; Partridge, Ann; Abravanel, Daniel; Jeselsohn, Rinath; Wrabel, Eileen; Alberti, Jillian; DiLullo, Molly; Chen, Serenity; Mohammed-Abreu, Ayesha; Sun, Xiaopeng; Balko, Justin M; Kleijn, Miranda; Audeh, William; Morgan, Xochitl C; Krop, Ian E; Tayob, Nabihah; Van Allen, Eliezer M; Mittendorf, Elizabeth A; Tolaney, Sara M

Monitoring systemic immune responses to checkpoint inhibition in breast cancer reveals host responses and mechanisms of resistance

监测乳腺癌中针对免疫检查点抑制剂的系统性免疫反应,可以揭示宿主反应和耐药机制。

Hanna, Ann; Sun, Xiaopeng; Sheng, Quanhu; Gonzalez-Ericsson, Paula I; Wescott, Elizabeth C; Taylor, Brandie C; Marshall, Jacey L; Opalenik, Susan R; Toren, Abigail L; Sanchez, Violeta; Fielder, Carly M; Sanders, Melinda E; Balko, Justin M

Progesterone receptor-dependent downregulation of MHC class I promotes tumor immune evasion and growth in breast cancer.

孕激素受体依赖性MHC I类分子下调促进乳腺癌肿瘤的免疫逃逸和生长

Tinoco Julio C, Saunders Harmony I, Werner Lauryn Rose, Sun Xiaopeng, Chowanec Eilidh I, Heard Amanda, Chalise Prabhakar, Vahrenkamp Jeffery M, Wilson Andrea E, Liu Cong-Xiao, Lei Gangjun, Wei Junping, Cros Hugo, Mohammed Hisham, Troester Melissa, Perou Charles, Markiewicz Mary A, Gertz Jason, Balko Justin M, Hartman Zachary Conrad, Hagan Christy R

Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer

氟维司群、帕博西尼和厄达替尼(一种泛FGFR酪氨酸激酶抑制剂)治疗HR+/HER2-转移性乳腺癌的Ib期试验

Gonzalez-Ericsson, Paula I; Unni, Nisha; Jhaveri, Komal; Stringer-Reasor, Erica; Liu, Qi; Wang, Yu; Sanchez, Violeta; Garcia, Guadalupe; Sanders, Melinda E; Lehmann, Brian D; Balko, Justin M; Park, Ben; Rexer, Brent N; Mayer, Ingrid A; Arteaga, Carlos L

The Impact of JAK1 Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer

JAK1致病变异和MHC-I表达对子宫内膜癌免疫检查点抑制剂治疗反应的影响

Carballo, Erica V; Gonzalez-Ericsson, Paula; Lehmann, Brian D; Taylor, Brandie C; Wulfkuhle, Julia D; Ocampo, Andres; Gallagher, Rosa I; Huang, Dandi S; Maxey, Christina; Steele, Julia A; Kleinberg, Katherine; Sun, Xiaopeng; Marshall, Jacey L; Sanchez, Violeta; Opalenik, Susan R; Petricoin, Emanuel; Rimel, B J; Balko, Justin M; Penn, Courtney A